Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T; MSBase study group. He A, et al. Among authors: coles a. Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199096
MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences.
Gawne-Cain ML, O'Riordan JI, Coles A, Newell B, Thompson AJ, Miller DH. Gawne-Cain ML, et al. Among authors: coles a. J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):197-203. doi: 10.1136/jnnp.64.2.197. J Neurol Neurosurg Psychiatry. 1998. PMID: 9489530 Free PMC article. Clinical Trial.
Recurrent myelitis and optic neuritis in a 29-year-old woman.
Cox A, Coles A, Antoun N, Malik O, Lucchinnetti C, Compston A. Cox A, et al. Among authors: coles a. Lancet Neurol. 2005 Aug;4(8):510-6. doi: 10.1016/S1474-4422(05)70143-5. Lancet Neurol. 2005. PMID: 16033693 No abstract available.
Multiple sclerosis.
Compston A, Coles A. Compston A, et al. Among authors: coles a. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7. Lancet. 2008. PMID: 18970977 Free article.
Multiple sclerosis.
Coles A. Coles A. Pract Neurol. 2009 Apr;9(2):118-26. doi: 10.1136/jnnp.2008.171132. Pract Neurol. 2009. PMID: 19289565 Review. No abstract available.
New treatment strategies in multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Jones JL, et al. Among authors: coles aj. Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21. Brain. 2010. PMID: 20659956 Clinical Trial.
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon beta-1a in a …
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [ …
297 results